View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsShedir Pharma Group 향후 성장Future 기준 점검 3/6Shedir Pharma Group (는) 각각 연간 7.9% 및 6.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 7.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.7% 로 예상됩니다.핵심 정보7.9%이익 성장률7.75%EPS 성장률Pharmaceuticals 이익 성장10.7%매출 성장률6.3%향후 자기자본이익률12.65%애널리스트 커버리지Low마지막 업데이트15 Oct 2024최근 향후 성장 업데이트Major Estimate Revision • Apr 12Consensus EPS estimates increase by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €56.5m to €57.5m. EPS estimate increased from €0.50 to €0.55 per share. Net income forecast to grow 37% next year vs 17% growth forecast for Pharmaceuticals industry in Italy. Consensus price target up from €7.62 to €7.93. Share price rose 6.8% to €4.38 over the past week.Price Target Changed • May 21Price target decreased to €5.20Down from €6.00, the current price target is an average from 2 analysts. New target price is 22% above last closing price of €4.26. Stock is up 5.4% over the past year.Price Target Changed • Oct 24Price target lowered to €6.95Down from €7.53, the current price target is an average from 2 analysts. The new target price is 64% above the current share price of €4.23. As of last close, the stock is down 43% over the past year.모든 업데이트 보기Recent updates분석 기사 • Nov 08Shedir Pharma Group S.p.A.'s (BIT:SHE) Share Price Boosted 25% But Its Business Prospects Need A Lift TooShedir Pharma Group S.p.A. ( BIT:SHE ) shareholders have had their patience rewarded with a 25% share price jump in the...New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 3.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (3.6% average weekly change). Market cap is less than US$100m (€47.0m market cap, or US$50.6m).Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €4.84, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 14x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 13% over the past three years.Reported Earnings • Sep 29First half 2024 earnings released: EPS: €0.14 (vs €0.10 in 1H 2023)First half 2024 results: EPS: €0.14 (up from €0.10 in 1H 2023). Revenue: €29.8m (up 5.5% from 1H 2023). Net income: €1.56m (up 32% from 1H 2023). Profit margin: 5.2% (up from 4.2% in 1H 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Sep 09Now 22% overvaluedOver the last 90 days, the stock has fallen 1.5% to €3.92. The fair value is estimated to be €3.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 20%.Buy Or Sell Opportunity • Aug 02Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 4.9% to €3.86. The fair value is estimated to be €3.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 20%.분석 기사 • Apr 05Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its ProblemsInvestors were disappointed by Shedir Pharma Group S.p.A.'s ( BIT:SHE ) latest earnings release. We did some further...Valuation Update With 7 Day Price Move • Feb 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €3.78, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 13x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 23% over the past three years.Upcoming Dividend • May 01Upcoming dividend of €0.17 per share at 3.4% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Trailing yield: 3.4%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (2.5%).Upcoming Dividend • Apr 25Upcoming dividend of €0.17 per share at 3.5% yieldEligible shareholders must have bought the stock before 02 May 2023. Payment date: 04 May 2023. Trailing yield: 3.5%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (2.5%).Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €5.00, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 13% over the past three years.Major Estimate Revision • Apr 12Consensus EPS estimates increase by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €56.5m to €57.5m. EPS estimate increased from €0.50 to €0.55 per share. Net income forecast to grow 37% next year vs 17% growth forecast for Pharmaceuticals industry in Italy. Consensus price target up from €7.62 to €7.93. Share price rose 6.8% to €4.38 over the past week.Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €4.28, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 36% over the past three years.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Marco Mazzarese was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0.06 in 1H 2021)First half 2022 results: EPS: €0. Revenue: €23.8m (up 26% from 1H 2021). Net income: €987.0k (up 45% from 1H 2021). Profit margin: 4.2% (up from 3.6% in 1H 2021). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to €3.30, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 17% over the past year.Upcoming Dividend • May 02Upcoming dividend of €0.13 per shareEligible shareholders must have bought the stock before 09 May 2022. Payment date: 11 May 2022. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of Italian dividend payers (4.7%). Higher than average of industry peers (2.5%).Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Marco Mazzarese was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 19Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: €0.34 (vs €0.34 in FY 2020). Revenue: €44.8m (up 3.8% from FY 2020). Net income: €3.93m (flat on FY 2020). Profit margin: 8.8% (down from 9.1% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 9.7%, compared to a 7.0% growth forecast for the pharmaceuticals industry in Italy.분석 기사 • Oct 05Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They SeemShedir Pharma Group S.p.A.'s ( BIT:SHE ) solid earnings announcement recently didn't do much to the stock price. We did...Reported Earnings • Oct 03First half 2021 earnings releasedThe company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €18.5m (down 3.5% from 1H 2020). Net income: €681.0k (down 42% from 1H 2020). Profit margin: 3.7% (down from 6.1% in 1H 2020). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to €4.92, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 28% over the past year.Price Target Changed • May 21Price target decreased to €5.20Down from €6.00, the current price target is an average from 2 analysts. New target price is 22% above last closing price of €4.26. Stock is up 5.4% over the past year.분석 기사 • Apr 06Is Shedir Pharma Group (BIT:SHE) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is New 90 Day High Low • Feb 04New 90-day low: €3.42The company is down 25% from its price of €4.55 on 05 November 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.14 per share.Is New 90 Day High Low • Jan 18New 90-day low: €3.54The company is down 12% from its price of €4.04 on 20 October 2020. The Italian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.18 per share.분석 기사 • Dec 30What Type Of Returns Would Shedir Pharma Group's(BIT:SHE) Shareholders Have Earned If They Purchased Their SharesYear Ago?Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...Is New 90 Day High Low • Dec 01New 90-day low: €3.72The company is down 10.0% from its price of €4.14 on 01 September 2020. The Italian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.93 per share.Is New 90 Day High Low • Oct 26New 90-day high: €4.39The company is up 6.0% from its price of €4.14 on 28 July 2020. The Italian market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.90 per share.Price Target Changed • Oct 24Price target lowered to €6.95Down from €7.53, the current price target is an average from 2 analysts. The new target price is 64% above the current share price of €4.23. As of last close, the stock is down 43% over the past year.Is New 90 Day High Low • Oct 02New 90-day low: €3.97The company is down 14% from its price of €4.59 on 03 July 2020. The Italian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.64 per share.이익 및 매출 성장 예측BIT:SHE - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20277681013112/31/20267271012112/31/2025687811112/31/202464691116/30/202461669N/A3/31/202460615N/A12/31/2023596-41N/A9/30/2023596-30N/A6/30/2023586-20N/A3/31/202356601N/A12/31/202253613N/A9/30/202251557N/A6/30/20224941011N/A3/31/20224741012N/A12/31/20214541012N/A9/30/2021444810N/A6/30/202143379N/A3/31/202143489N/A12/31/2020434910N/A9/30/202044357N/A6/30/202045313N/A3/31/2020473-4-1N/A12/31/2019513-5-3N/A9/30/2019504-3-1N/A6/30/2019495-10N/A3/31/201949667N/A12/31/2018477-3-1N/A12/31/2017403N/A5N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SHE 의 연간 예상 수익 증가율(7.9%)이 saving rate(2.5%)보다 높습니다.수익 vs 시장: SHE 의 연간 수익(7.9%)이 Italian 시장(11.1%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: SHE 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: SHE 의 수익(연간 6.3%)이 Italian 시장(연간 5.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: SHE 의 수익(연간 6.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SHE의 자본 수익률은 3년 후 12.7%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/01/24 07:34종가2025/01/22 00:00수익2024/06/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Shedir Pharma Group S.p.A.는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gian GadiniBanca Akros S.p.A. (ESN)Maria Di GradoKT & Partners Srl
Major Estimate Revision • Apr 12Consensus EPS estimates increase by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €56.5m to €57.5m. EPS estimate increased from €0.50 to €0.55 per share. Net income forecast to grow 37% next year vs 17% growth forecast for Pharmaceuticals industry in Italy. Consensus price target up from €7.62 to €7.93. Share price rose 6.8% to €4.38 over the past week.
Price Target Changed • May 21Price target decreased to €5.20Down from €6.00, the current price target is an average from 2 analysts. New target price is 22% above last closing price of €4.26. Stock is up 5.4% over the past year.
Price Target Changed • Oct 24Price target lowered to €6.95Down from €7.53, the current price target is an average from 2 analysts. The new target price is 64% above the current share price of €4.23. As of last close, the stock is down 43% over the past year.
분석 기사 • Nov 08Shedir Pharma Group S.p.A.'s (BIT:SHE) Share Price Boosted 25% But Its Business Prospects Need A Lift TooShedir Pharma Group S.p.A. ( BIT:SHE ) shareholders have had their patience rewarded with a 25% share price jump in the...
New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 3.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (3.6% average weekly change). Market cap is less than US$100m (€47.0m market cap, or US$50.6m).
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €4.84, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 14x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 13% over the past three years.
Reported Earnings • Sep 29First half 2024 earnings released: EPS: €0.14 (vs €0.10 in 1H 2023)First half 2024 results: EPS: €0.14 (up from €0.10 in 1H 2023). Revenue: €29.8m (up 5.5% from 1H 2023). Net income: €1.56m (up 32% from 1H 2023). Profit margin: 5.2% (up from 4.2% in 1H 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Sep 09Now 22% overvaluedOver the last 90 days, the stock has fallen 1.5% to €3.92. The fair value is estimated to be €3.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 20%.
Buy Or Sell Opportunity • Aug 02Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 4.9% to €3.86. The fair value is estimated to be €3.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 20%.
분석 기사 • Apr 05Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its ProblemsInvestors were disappointed by Shedir Pharma Group S.p.A.'s ( BIT:SHE ) latest earnings release. We did some further...
Valuation Update With 7 Day Price Move • Feb 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €3.78, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 13x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 23% over the past three years.
Upcoming Dividend • May 01Upcoming dividend of €0.17 per share at 3.4% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Trailing yield: 3.4%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (2.5%).
Upcoming Dividend • Apr 25Upcoming dividend of €0.17 per share at 3.5% yieldEligible shareholders must have bought the stock before 02 May 2023. Payment date: 04 May 2023. Trailing yield: 3.5%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (2.5%).
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €5.00, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 13% over the past three years.
Major Estimate Revision • Apr 12Consensus EPS estimates increase by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €56.5m to €57.5m. EPS estimate increased from €0.50 to €0.55 per share. Net income forecast to grow 37% next year vs 17% growth forecast for Pharmaceuticals industry in Italy. Consensus price target up from €7.62 to €7.93. Share price rose 6.8% to €4.38 over the past week.
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €4.28, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 36% over the past three years.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Marco Mazzarese was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0.06 in 1H 2021)First half 2022 results: EPS: €0. Revenue: €23.8m (up 26% from 1H 2021). Net income: €987.0k (up 45% from 1H 2021). Profit margin: 4.2% (up from 3.6% in 1H 2021). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to €3.30, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 17% over the past year.
Upcoming Dividend • May 02Upcoming dividend of €0.13 per shareEligible shareholders must have bought the stock before 09 May 2022. Payment date: 11 May 2022. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of Italian dividend payers (4.7%). Higher than average of industry peers (2.5%).
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Marco Mazzarese was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 19Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: €0.34 (vs €0.34 in FY 2020). Revenue: €44.8m (up 3.8% from FY 2020). Net income: €3.93m (flat on FY 2020). Profit margin: 8.8% (down from 9.1% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 9.7%, compared to a 7.0% growth forecast for the pharmaceuticals industry in Italy.
분석 기사 • Oct 05Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They SeemShedir Pharma Group S.p.A.'s ( BIT:SHE ) solid earnings announcement recently didn't do much to the stock price. We did...
Reported Earnings • Oct 03First half 2021 earnings releasedThe company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €18.5m (down 3.5% from 1H 2020). Net income: €681.0k (down 42% from 1H 2020). Profit margin: 3.7% (down from 6.1% in 1H 2020). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to €4.92, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 28% over the past year.
Price Target Changed • May 21Price target decreased to €5.20Down from €6.00, the current price target is an average from 2 analysts. New target price is 22% above last closing price of €4.26. Stock is up 5.4% over the past year.
분석 기사 • Apr 06Is Shedir Pharma Group (BIT:SHE) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Is New 90 Day High Low • Feb 04New 90-day low: €3.42The company is down 25% from its price of €4.55 on 05 November 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.14 per share.
Is New 90 Day High Low • Jan 18New 90-day low: €3.54The company is down 12% from its price of €4.04 on 20 October 2020. The Italian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.18 per share.
분석 기사 • Dec 30What Type Of Returns Would Shedir Pharma Group's(BIT:SHE) Shareholders Have Earned If They Purchased Their SharesYear Ago?Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...
Is New 90 Day High Low • Dec 01New 90-day low: €3.72The company is down 10.0% from its price of €4.14 on 01 September 2020. The Italian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.93 per share.
Is New 90 Day High Low • Oct 26New 90-day high: €4.39The company is up 6.0% from its price of €4.14 on 28 July 2020. The Italian market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.90 per share.
Price Target Changed • Oct 24Price target lowered to €6.95Down from €7.53, the current price target is an average from 2 analysts. The new target price is 64% above the current share price of €4.23. As of last close, the stock is down 43% over the past year.
Is New 90 Day High Low • Oct 02New 90-day low: €3.97The company is down 14% from its price of €4.59 on 03 July 2020. The Italian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.64 per share.